Hereditary breast cancer: From molecular pathology to tailored therapies

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1

Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069 · see citing works

Repeated observation of breast tumor subtypes in independent gene expression data sets

Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,428 · see citing works

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works

Identification of the breast cancer susceptibility gene BRCA2

Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645 · see citing works

Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21

Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544 · see citing works

Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13

Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K. N., Seal, S., Tran, T. D., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,918 · see citing works

An Immunohistochemical Study

Isaacson, P. G., Doǧan, A., Price, S. K., & Spencer, J. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198912000-00004 · Cited by 1,913 · see citing works

Hallmarks of 'BRCAness' in sporadic cancers

Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,651 · see citing works

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311 · see citing works

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,288 · see citing works

Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors

Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · see citing works

Biallelic Inactivation of <i>BRCA2</i> in Fanconi Anemia

Howlett, N. G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., de Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G., et al. (2002) · Science · doi:10.1126/science.1073834 · Cited by 1,149 · see citing works

Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104 · see citing works

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · see citing works

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

Rahman, N., Seal, S., Thompson, D. J., Kelly, P. F., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., Chagtai, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1959 · Cited by 1,002 · see citing works

Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

Foulkes, W. D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg050 · Cited by 970 · see citing works

BRCA1 and BRCA2: 1994 and beyond

Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967 · see citing works

Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.

Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D., Evans, C., Deacon, J., & Stratton, M. R. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.943 · Cited by 909 · see citing works

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Lakhani, S., van de Vijver, M., Jacquemier, J., Anderson, T., Osin, P., McGuffog, L., & Easton, D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 888 · see citing works

The BRCT Domain Is a Phospho-Protein Binding Domain

Yu, X., Chini, C. C. S., He, M., Mer, G., & Chen, J. (2003) · Science · doi:10.1126/science.1088753 · Cited by 862 · see citing works

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 857 · see citing works

Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals

Frank, T. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1480 · Cited by 813 · see citing works

Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

van der Groep, P., Bouter, A., van der Zanden, R. A., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798 · see citing works

Genetic instability and darwinian selection in tumours

Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Christoph Lengauer, C. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01661-x · Cited by 747 · see citing works

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

The Breast Cancer Susceptibility Collaboration (UK), Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, H., Ahmed, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1902 · Cited by 746 · see citing works

Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations

Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707 · see citing works

The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.

Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81302-1 · Cited by 680 · see citing works

Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer

Reid, S., Schindler, D., Hanenberg, H., Barker, K., Hanks, S., Kalb, R., Neveling, K., Kelly, P., Seal, S., Freund, M., et al. (2007) · Nature Genetics · doi:10.1038/ng1947 · Cited by 642 · see citing works

Involvement of Brca2 in DNA Repair

Patel, K. J., Yu, V. P. C. C., Lee, H., Corcoran, A. E., Thistlethwaite, F. C., Evans, M. J., Colledge, W. H., Friedman, L. S., Ponder, B. A. J., & Venkitaraman, A. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80035-0 · Cited by 631 · see citing works

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

Gudmundsdottir, K. K., & Ashworth, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209874 · Cited by 625 · see citing works

Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

Lakhani, S. R., Reis-Filho, J. S., Fulford, L. G., Penault-Llorca, F. M., van de Vijver, M. J., Parry, S., Bishop, D. T., Benitez, J. J., Rivas, C., Bignon, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2424 · Cited by 611 · see citing works

Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases

Anglian Breast Cancer Study Group (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 602 · see citing works

Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579 · see citing works

BRCA1 dysfunction in sporadic basal-like breast cancer

Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 574 · see citing works

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer

Bergamaschi, A., Kim, Y. H., Wang, P., Sørlie, T., Hernandez‐Boussard, T., Lønning, P. E., Tibshirani, R. J., Børresen‐Dale, A., & Pollack, J. R. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20366 · Cited by 506 · see citing works

Variation in Cancer Risks, by Mutation Position, in BRCA2 Mutation Carriers

Thompson, D. J., & Easton, D. F. (2001) · The American Journal of Human Genetics · doi:10.1086/318181 · Cited by 492 · see citing works

The emerging landscape of breast cancer susceptibility

Stratton, M. R., & Rahman, N. (2008) · Nature Genetics · doi:10.1038/ng.2007.53 · Cited by 487 · see citing works

Basal-like breast cancer and the BRCA1 phenotype

Turner, N. C., & Reis-Filho, J. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209876 · Cited by 481 · see citing works

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer

Liu, X., Holstege, H. H., van der Gulden, H. M. L., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 474 · see citing works

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2

Xia, B., Dorsman, J. C., Ameziane, N., de Vries, Y., Rooimans, M. A., Sheng, Q., Pals, G., Errami, A., Gluckman, E., Llera, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1942 · Cited by 465 · see citing works

Improved survival in women with BRCA‐associated ovarian carcinoma

Cass, I. A., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 431 · see citing works

The Role of BRCA1 in the Cellular Response to Chemotherapy

Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh312 · Cited by 429 · see citing works

EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer

Hughes‐Davies, L., Huntsman, D. D., Ruas, M., Fuks, F., Bye, J. M., Chin, S., Milner, J., Brown, L. A., Hsu, F. D., Gilks, C. B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 422 · see citing works

ATM and ataxia telangiectasia

McKinnon, P. J. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400210 · Cited by 365 · see citing works

Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation

Powell, S. N., & Kachnic, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206678 · Cited by 364 · see citing works

Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics

Catteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354 · see citing works

Metaplastic breast carcinomas are basal‐like tumours

Reis-Filho, J. S., Milanezi, F., Steele, D., et al. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02467.x · Cited by 341 · see citing works

Estrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast Cancer

Foulkes, W. D., Metcalfe, K. A., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-1061 · Cited by 293 · see citing works

Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1.

Williams, R. S., Green, R., & Glover, J. N. M. (2001) · Nature Structural Biology · doi:10.1038/nsb1001-838 · Cited by 292 · see citing works

Partial rescue of Brca15–6 early embryonic lethality by p53 or p21 null mutation

Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., & Mak, T. W. (1997) · Nature Genetics · doi:10.1038/ng0797-298 · Cited by 252 · see citing works

Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

Lakhani, S. R., Manek, S., Penault-Llorca, F. M., Flanagan, A. M., Arnout, L., Merrett, S., McGuffog, L., Steele, D., Devilee, P., Klijn, J. G. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1029-3 · Cited by 252 · see citing works

Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.

Wessels, L. F. A., van Welsem, T., Hart, A. A. M., Veer, L. J. V., Reinders, M. J. T., & Nederlof, P. M. (2002) · PubMed · Cited by 252 · see citing works

Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

Armes, J. E., Trute, L., White, D., Southey, M. C., Hammet, F., Tesoriero, A. A., Hutchins, A., Dite, G. S., McCredie, M. R. E., Giles, G. G., et al. (1999) · PubMed · Cited by 236 · see citing works

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.

Lakhani, S. R., Gusterson, B. A., Jacquemier, J. D., Sloane, J. P., Anderson, T. J., van de Vijver, M. J., Venter, D. J., Freeman, A., Antoniou, A., McGuffog, L., et al. (2000) · PubMed · Cited by 222 · see citing works

The CHEK2 gene and inherited breast cancer susceptibility

Nevanlinna, H. A., & Bártek, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209877 · Cited by 221 · see citing works

Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way

Santarosa, M., & Ashworth, A. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.01.001 · Cited by 215 · see citing works

Analysis of PALB2 / FANCN -associated breast cancer families

Tischkowitz, M. D., Xia, B., Sabbaghian, N., Reis-Filho, J. S., Hamel, N., Li, G., van Beers, E. H., Li, L., Khalil, T., Quenneville, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701724104 · Cited by 211 · see citing works

BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

Quinn, J. E., James, C. R., Stewart, G. E., Mulligan, J. M., White, P., Chang, G. K. F., Mullan, P. B., Johnston, P. G., Wilson, R. H., & Harkin, D. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1083 · Cited by 208 · see citing works

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for CancerPreprint

Tutt, A. N. J., Lord, C. J., McCabe, N., Farmer, H., Turner, N. C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 195 · see citing works

Germline E-cadherin mutations in familial lobular breast cancer

啓三, 中., 通佳, 河., Senz, J., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.051268 · Cited by 190 · see citing works

The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications

Honrado, E., Benitez, J. J., & Palacios, J. (2005) · Modern Pathology · doi:10.1038/modpathol.3800453 · Cited by 190 · see citing works

BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays

Bane, A., Beck, J., Bleiweiss, I., Buys, S., Catalano, E., Daly, M., Giles, G., Godwin, A., Hibshoosh, H., Hopper, J., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213351.49767.0f · Cited by 181 · see citing works

p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

Crook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philp, E., Smith, P. D., Yuluğ, I. G., Peto, J., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202106 · Cited by 179 · see citing works

Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.

Palacios, J., Honrado, E., Osório, A., Cazorla, A., Sarrió, D., Barroso, A., Rodríguez, S., Cigudosa, J. C., Dı́ez, O., Alonso, C., et al. (2003) · PubMed · Cited by 175 · see citing works

The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis

Lucas, K. G., Brown, A. E., Armstrong, D., Chapman, D. S., & Heller, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4 · Cited by 174 · see citing works

BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy

Wei, M., Grushko, T. A., Dignam, J. J., Hagos, F., Nanda, R., Sveen, L., Xu, J., Fackenthal, J. D., Tretiakova, M., Das, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1277 · Cited by 170 · see citing works

Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas

Simpson, P. T., Reis‐Filho, J., Lambros, M., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2358 · Cited by 169 · see citing works

BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

Matros, E., Wang, Z. C., Lodeiro, G., Miron, A., Iglehart, J. D., & Richardson, A. L. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-7603-8 · Cited by 165 · see citing works

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

Palacios, J., Honrado, E., Osório, A., Cazorla, A., Sarrió, D., Barroso, A., Rodríguez, S., Cigudosa, J. C., Dı́ez, O., Alonso, C., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1536-0 · Cited by 165 · see citing works

Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis

Reis-Filho, J. S., Savage, K., Lambros, M. B. K., James, M., Steele, D., Jones, R. L., & Dowsett, M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800621 · Cited by 163 · see citing works

Targeting the DNA repair defect of BRCA tumours

Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.006 · Cited by 162 · see citing works

Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer

Arnes, J. B., Brunet, J., Stefansson, I. M., Bégin, L. R., Wong, N., Chappuis, P. O., Akslen, L. A., & Foulkes, W. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2064 · Cited by 158 · see citing works

Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization

Jönsson, G. B., Naylor, T. L., Vallon‐Christersson, J., Staaf, J., Huang, J., Ward, M. R., Greshock, J. D., Luts, L., Olsson, H. L., Rahman, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0570 · Cited by 158 · see citing works

Expression of BRCA1 protein in breast cancer and its prognostic significance

Rakha, E. A., Elsheikh, S. E., Kandil, M. A. E.-H., et al. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.10.011 · Cited by 153 · see citing works

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency

McCabe, N., Lord, C. J., Tutt, A. N. J., Martin, N. M. B., Smith, G. C. M., & Ashworth, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.9.2141 · Cited by 149 · see citing works

A mouse model of basal‐like breast carcinoma with metaplastic elements

McCarthy, A., Savage, K., Gabriel, A., Naceur‐Lombardelli, C., Reis‐Filho, J., & Ashworth, A. (2007) · The Journal of Pathology · doi:10.1002/path.2124 · Cited by 142 · see citing works

Nijmegen Breakage Syndrome mutations and risk of breast cancer

Bogdanova, N. V., Feshchenko, S., Schürmann, P., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23168 · Cited by 139 · see citing works

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer

Rodríguez-Pinilla, S. M., Honrado, E., Hardisson, D., Benitez, J. J., & Palacios, J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9184-1 · Cited by 135 · see citing works

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers

Letessier, A., Sircoulomb, F., Ginestier, C., Cervera, N., Monville, F., Gelsi‐Boyer, V., Esterni, B., Geneix, J., Finetti, P., Zemmour, C., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-245 · Cited by 134 · see citing works

Comparative Genomic Hybridization Profiles in Human BRCA1 and BRCA2 Breast Tumors Highlight Differential Sets of Genomic Aberrations

van Beers, E. H., van Welsem, T., Wessels, L. F. A., Li, Y., Oldenburg, R. A., Devilee, P., Cornelisse, C. J., Verhoef, S., Hogervorst, F. B. L., Veer, L. J. V., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.822.65.3 · Cited by 129 · see citing works

CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas

Holland, E. A., Schmid, H., Kefford, R. F., & Mann, G. J. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199908)25:4 · Cited by 112 · see citing works

Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations

Honrado, E., Osório, A., Palacios, J., & Benitez, J. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209875 · Cited by 108 · see citing works

Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1 -associated breast carcinomas

Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., et al. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.042143 · Cited by 106 · see citing works

Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers

Collins, N., Wooster, R., & Stratton, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.526 · Cited by 101 · see citing works

Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data

van der Groep, P., Bouter, A., van der Zanden, R. A., et al. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.032151 · Cited by 101 · see citing works

Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.

Merajver, S. D., Frank, T. S., Xu, J., et al. (1995) · PubMed · Cited by 97 · see citing works

Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players

Rahman, N., & Scott, R. H. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm026 · Cited by 94 · see citing works

Pathology and heredity of breast cancer in younger women.

Marcus, J. N., Watson, P. A., Page, D. L., et al. (1994) · PubMed · Cited by 84 · see citing works

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2and mutation-negative breast cancer families

Eerola, H., Heikkilä, P., Tamminen, A., Aittomäki, K., BLOMQVIST, C. P., & Nevanlinna, H. A. (2005) · Breast Cancer Research · doi:10.1186/bcr1025 · Cited by 80 · see citing works

High frequency of HIF-1α overexpression in BRCA1 related breast cancer

van der Groep, P., Bouter, A., Menko, F. H., van der Wall, E., & van Diest, P. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9817-z · Cited by 79 · see citing works

Ductal Carcinoma In Situ in BRCA Mutation Carriers

Hwang, E. S., McLennan, J., Moore, D. H., Crawford, B. B., Esserman, L. J., & Ziegler, J. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0345 · Cited by 77 · see citing works

Clinical Classification ofBRCA1andBRCA2DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the kConFab Investigators

Spurdle, A. B., Lakhani, S. R., Healey, S. C., Parry, S., Silva, L. M. D., Brinkworth, R. I., Hopper, J. L., Brown, M. A., Babikyan, D., Chenevix‐Trench, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2779 · Cited by 74 · see citing works

Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

Vaziri, S. A. J., Krumroy, L. M., Elson, P. J., Budd, G. T., Darlington, G., Myles, J., Tubbs, R. R., & Casey, G. (2001) · PubMed · Cited by 73 · see citing works

Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.

Seal, S., Barfoot, R., Jayatilake, H., Smith, P., Renwick, A., Bascombe, L., McGuffog, L., Evans, D. G., Eccles, D., Easton, D. F., et al. (2003) · PubMed · Cited by 72 · see citing works

Evaluation of RAD50 in familial breast cancer predisposition

Tommiska, J., Seal, S., Renwick, A., Barfoot, R., Baskcomb, L., Jayatilake, H., Bártková, J., Tallila, J., Kaare, M., Tamminen, A., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21738 · Cited by 65 · see citing works

Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer DifferentiateBRCA2-Associated Tumors

Honrado, E., Osório, A., Palacios, J., Milne, R. L., Sánchez, L., Dı́ez, O., Cazorla, A., Syrjäkoski, K., Huntsman, D. D., Heikkilä, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3698 · Cited by 65 · see citing works

Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome

Rodriguez, C., Hughes‐Davies, L., Vallès, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0410 · Cited by 65 · see citing works

Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition

Gallmeier, E., & Kern, S. E. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1909 · Cited by 62 · see citing works

HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry

Quenneville, L. A., Phillips, K., Ozçelik, H., Parkes, R., Knight, J., Goodwin, P., Andrulis, I., & O'Malley, F. (2002) · Cancer · doi:10.1002/cncr.10949 · Cited by 61 · see citing works

The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study

Pérez‐Vallés, A., Martorell-Cebollada, M., Nogueira-Vázquez, E., et al. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.6.476 · Cited by 57 · see citing works

ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers

Adem, C., Soderberg, C. L., Hafner, K. A., Reynolds, C. A., Slezak, J. M., Sinclair, C. S., Sellers, T. A., Schaid, D. J., Couch, F. J., Hartmann, L. C., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20057 · Cited by 52 · see citing works

Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer

van der Groep, P., Hoelzel, M., Buerger, H., Joenje, H., de Winter, J. P., & van Diest, P. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9534-7 · Cited by 52 · see citing works

Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families

Honrado, E., Osório, A., Milne, R. L., Paz, M. F., Melchor, L., Cascón, A., Urioste, M., Cazorla, A., Dı́ez, O., Lerma, E., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800969 · Cited by 50 · see citing works

Pathology of breast cancer in women with constitutional CHEK2 mutations

Huzarski, T., Cybulski, C., Domagała, W., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-3778-2 · Cited by 47 · see citing works

Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers

Vaziri, S. A. J., Tubbs, R. R., Darlington, G., et al. (2001) · Molecular Pathology · doi:10.1136/mp.54.4.259 · Cited by 44 · see citing works

Morphology of Breast Cancer as a Means of Triage of Patients for BRCA1 Genetic Testing

Farshid, G., Balleine, R. L., Cummings, M. C., et al. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213273.22844.1a · Cited by 44 · see citing works

Hereditary ovarian cancer.

Prat, J., Ribé, A., & Gallardo, A. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.06.006 · Cited by 44 · see citing works

Nijmegen Breakage Syndrome

Вадимовна, К. И., Paschenko, O., Polyakov, A., & Бологов, А. А. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_6 · Cited by 38 · see citing works

NBS1 variant I171V and breast cancer risk

Bogdanova, N. V., Schürmann, P., Waltes, R., Feshchenko, S., Zalutsky, I. V., Bremer, M., & Dörk, T. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9820-4 · Cited by 33 · see citing works

Model‐based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center

Shannon, K. M., Lubratovich, M., Finkelstein, D., Smith, B. L., Powell, S., & Seiden, M. (2002) · Cancer · doi:10.1002/cncr.10223 · Cited by 30 · see citing works

Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer

Shiu, K., Tan, D. S. P., & Reis-Filho, J. S. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.9.1123 · Cited by 23 · see citing works

Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma

Fuchs, J., Wenderoth, M., von Schweinitz, D., Haindl, J., & Leuschner, I. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11 · Cited by 23 · see citing works

Histopathological features of breast cancer in carriers of ATM gene variants

Balleine, R. L., Murali, R., Bilous, A. M., Farshid, G., Waring, P., Provan, P. J., Byth, K., Thorne, H., kConFab Investigators, & Kirk, J. A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02538.x · Cited by 20 · see citing works

Mutation analysis of five candidate genes in familial breast cancer

Marsh, A. J., Healey, S., Lewis, A., Spurdle, A. B., Kedda, M., Khanna, K. K., kConFab, Mann, G. J., Pupo, G. M., Lakhani, S. R., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9461-z · Cited by 19 · see citing works

Oh what a tangled web it weaves: BRCA1 and DNA decatenation

Ashworth, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.011 · Cited by 13 · see citing works

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

Management of familial melanoma

Newton‐Bishop, J., Harland, M., Randerson‐Moor, J. A., & Bishop, D. T. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)71010-5 · Cited by 64 · see citing works

Penetrance of adrenocortical tumours associated with the germline <i>TP53</i> R337H mutation

Figueiredo, B. C., Sandrini, R., Zambetti, G. P., Pereira, R. M., Cheng, C., Liu, W., Lacerda, L., Pianovski, M. A., Michalkiewicz, E., Jenkins, J., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030551 · Cited by 166 · see citing works

Low penetrance of a SDHB mutation in a large Dutch paraganglioma family

Hes, F. J., Weiss, M. M., Woortman, S. A., de Miranda, N. F. C. C., van Bunderen, P. A., Bonsing, B. A., Stokkel, M. P. M., Morreau, H., Romijn, J. A., Jansen, J. C., et al. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-92 · Cited by 53 · see citing works

Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers

Eijkelenkamp, K., Osinga, T. E., de Jong, M. M., Sluiter, W. J., Dullaart, R. P. F., Links, T. P., Kerstens, M. N., & van der Horst‐Schrivers, A. N. A. (2016) · Familial Cancer · doi:10.1007/s10689-016-9923-3 · Cited by 32 · see citing works

Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

Zweemer, R. P., Shaw, P. A., Verheijen, R. H. M., Ryan, A., Berchuck, A., Ponder, B. A. J., Risch, H. A., McLaughlin, J. R., Narod, S. A., Menko, F. H., et al. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.5.372 · Cited by 45 · see citing works